ATOS - Atossa Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
0
0
0
0
0
Operating Expenses
Research Development
15,083
15,083
9,210
6,608
6,645
Selling General and Administrative
12,608
12,608
11,311
7,999
10,620
Total Operating Expenses
27,691
27,691
20,521
14,607
17,265
Operating Income or Loss
-27,691
-27,691
-20,521
-14,607
-17,265
Total Other Income/Expenses Net
-146
-146
-85
-3,221
25.648
Income Before Tax
-26,960
-26,960
-20,606
-17,828
-17,240
Income Tax Expense
0
0
0
0
0
Income from Continuing Operations
-26,960
-26,960
-20,606
-17,828
-17,240
Net Income
-26,960
-26,960
-20,606
-17,828
-17,240
Net Income available to common shareholders
-26,960
-26,960
-20,606
-22,331
-17,240
Basic EPS
-
-0.21
-0.18
-1.97
-2.03
Diluted EPS
-
-0.21
-0.18
-1.97
-2.03
Basic Average Shares
-
126,624
116,950
11,309
8,497
Diluted Average Shares
-
126,624
116,950
11,309
8,497
EBITDA
-
-27,691
-20,498
-14,561
-17,213